Literature DB >> 22466654

Chromosomal instability and cancer: a complex relationship with therapeutic potential.

Samuel F Bakhoum1, Duane A Compton.   

Abstract

Chromosomal instability (CIN) is a hallmark of human neoplasms. Despite its widespread prevalence, knowledge of the mechanisms and contributions of CIN in cancer has been elusive. It is now evident that the role of CIN in tumor initiation and growth is more complex than previously thought. Furthermore, distinguishing CIN, which consists of elevated rates of chromosome missegregation, from aneuploidy, which is a state of abnormal chromosome number, is crucial to understanding their respective contributions in cancer. Collectively, experimental evidence suggests that CIN enables tumor adaptation by allowing tumors to constantly sample the aneuploid fitness landscape. This complex relationship, together with the potential to pharmacologically influence chromosome missegregation frequencies in cancer cells, offers previously unrecognized means to limit tumor growth and its response to therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22466654      PMCID: PMC3314464          DOI: 10.1172/JCI59954

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  80 in total

Review 1.  Spindle assembly in animal cells.

Authors:  D A Compton
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

Review 2.  Merotelic kinetochore orientation, aneuploidy, and cancer.

Authors:  Daniela Cimini
Journal:  Biochim Biophys Acta       Date:  2008-05-23

3.  A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers.

Authors:  Scott L Carter; Aron C Eklund; Isaac S Kohane; Lyndsay N Harris; Zoltan Szallasi
Journal:  Nat Genet       Date:  2006-08-20       Impact factor: 38.330

Review 4.  Trisomy 8 as the sole chromosomal aberration in acute myeloid leukemia and myelodysplastic syndromes.

Authors:  K Paulsson; B Johansson
Journal:  Pathol Biol (Paris)       Date:  2006-05-11

5.  Whole chromosome instability caused by Bub1 insufficiency drives tumorigenesis through tumor suppressor gene loss of heterozygosity.

Authors:  Darren J Baker; Fang Jin; Karthik B Jeganathan; Jan M van Deursen
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

6.  The optimal rate of chromosome loss for the inactivation of tumor suppressor genes in cancer.

Authors:  Natalia L Komarova; Dominik Wodarz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-22       Impact factor: 11.205

7.  Sensing chromosome bi-orientation by spatial separation of aurora B kinase from kinetochore substrates.

Authors:  Dan Liu; Gerben Vader; Martijn J M Vromans; Michael A Lampson; Susanne M A Lens
Journal:  Science       Date:  2009-01-15       Impact factor: 47.728

Review 8.  The spindle-assembly checkpoint in space and time.

Authors:  Andrea Musacchio; Edward D Salmon
Journal:  Nat Rev Mol Cell Biol       Date:  2007-04-11       Impact factor: 94.444

9.  Low rates of aneuploidy promote tumorigenesis while high rates of aneuploidy cause cell death and tumor suppression.

Authors:  Beth A A Weaver; Alain D Silk; Don W Cleveland
Journal:  Cell Oncol       Date:  2008       Impact factor: 6.730

10.  Genome stability is ensured by temporal control of kinetochore-microtubule dynamics.

Authors:  Samuel F Bakhoum; Sarah L Thompson; Amity L Manning; Duane A Compton
Journal:  Nat Cell Biol       Date:  2008-12-07       Impact factor: 28.824

View more
  117 in total

1.  Sirtuin-3 (SIRT3) and the Hallmarks of Cancer.

Authors:  Turki Y Alhazzazi; Pachiyappan Kamarajan; Eric Verdin; Yvonne L Kapila
Journal:  Genes Cancer       Date:  2013-03

2.  JNK signaling is needed to tolerate chromosomal instability.

Authors:  Heidi W-S Wong; Zeeshan Shaukat; Jianbin Wang; Robert Saint; Stephen L Gregory
Journal:  Cell Cycle       Date:  2013-12-12       Impact factor: 4.534

Review 3.  Targeting mitotic pathways for endocrine-related cancer therapeutics.

Authors:  Shivangi Agarwal; Dileep Varma
Journal:  Endocr Relat Cancer       Date:  2017-06-14       Impact factor: 5.678

Review 4.  Tumor cell plasticity: the challenge to catch a moving target.

Authors:  Sarah Schwitalla
Journal:  J Gastroenterol       Date:  2014-02-25       Impact factor: 7.527

5.  Correlation between smoking history and molecular pathways in sporadic colorectal cancer: a meta-analysis.

Authors:  Ke Chen; Guanggai Xia; Changhua Zhang; Yunwei Sun
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 6.  Building bridges between chromosomes: novel insights into the abscission checkpoint.

Authors:  Eleni Petsalaki; George Zachos
Journal:  Cell Mol Life Sci       Date:  2019-07-13       Impact factor: 9.261

7.  Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715.

Authors:  Roger B Slee; Brenda R Grimes; Ruchi Bansal; Jesse Gore; Corinne Blackburn; Lyndsey Brown; Rachel Gasaway; Jaesik Jeong; Jose Victorino; Keith L March; Riccardo Colombo; Brittney-Shea Herbert; Murray Korc
Journal:  Mol Cancer Ther       Date:  2013-11-26       Impact factor: 6.261

8.  STING Promotes Homeostasis via Regulation of Cell Proliferation and Chromosomal Stability.

Authors:  Diana Rose E Ranoa; Ryan C Widau; Stephen Mallon; Akash D Parekh; Claudia M Nicolae; Xiaona Huang; Michael J Bolt; Ainhoa Arina; Renate Parry; Stephen J Kron; George-Lucian Moldovan; Nikolai N Khodarev; Ralph R Weichselbaum
Journal:  Cancer Res       Date:  2018-11-27       Impact factor: 12.701

Review 9.  Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?

Authors:  Michael Hölzel; Anton Bovier; Thomas Tüting
Journal:  Nat Rev Cancer       Date:  2013-03-28       Impact factor: 60.716

Review 10.  Posttranslational modifications regulate HIPK2, a driver of proliferative diseases.

Authors:  Vera V Saul; M Lienhard Schmitz
Journal:  J Mol Med (Berl)       Date:  2013-04-25       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.